Peer review articles 1993 - 1995

63.       Dietel M: Second international symposium on cytostatic drug resistance. Meeting report.
Cancer Res 53: 2683-2688, 1993

64.       Dietel M, Bals U, Schaefer B, Herzig I, Arps H, Zabel M: In vitro prediction of cytostatic drug resistance in primary cell cultures of solid malignant tumors. Eur J Cancer 29: 416-420, 1993

65.       Reymann A, Looft G, Woermann C, Dietel M, Erttmann R: Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl. Cancer Chemother Pharmacol 32: 25-30, 1993

66.       Weh HJ, Agarwal K, Zornig C, Schwarz R, Dietel M, Hossfeld DK: Treatment results obtained in metastatic soft tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. Cancer Chemother Pharmacol 31(Suppl 2): S189-S193, 1993

67.       Dietel M, Herzig I, Reymann A, Brandt I, Schaefer B, Bunge A, Heidebrecht HJ, Seidel A: Secondary combined resistance to the multidrug resistance reversing activity of cyclosporin A in the cell line F4-6RADR-CsA. Cancer Res Clin Oncol  120: 263-271, 1994

68.       Holm PS, Scanlon KJ, Dietel M: Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by induvction of a hammerhead ribizyme. Br J Cancer 70: 239-243, 1994

69.       Dietel M: Die Polymerase-Kettenreaktion in der diagnostischen Pathologie. Verh. Dtsch. Ges Path 78: 136-145, 1994

70.       Braakhuis-BJ; Hill-BT; Dietel-M; Kelland-LR; Aapro-MS; Zoli-W; Lelieveld-P: In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer-Res. 14: 205-8, 1994

71.       Seidel A, Hasmann M, Löser D, Kohr A, Bunge A, Schaefer B, Herzig I, Heinemann G, Brandt I, Nickelsen M, Steidtmann K, Dietel M: Intracellular distribution and kinetics of daunorubicin in sensitive and multidrug-resistant EPG85-257. Virch Arch 426: 249-256, 1995

72.       Dietel M, Nicopoulos T, Reymann A, Pest S, Seidel A: In vivo reversibility of multidrug resistance by the niguldipine derivative B859-35 (dexniguldipine). J. Exp. Therap. Oncol, accepted, 1995

73.       Wiechen K, Dietel M: C-erbB-2 antisense phosphothioate oligonukleotides inhibit growth and serum-induced cell spreading of P185cerbB-2-overexpressing ovarian carcinoma cells. Int. J. Cancer, 63: 1-5, 1995